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1. Introduction 
Parkinson syndrome is one of the most often neurodegenerative diseases, which affects the 
Central Nervous system. James Parkinson was the first who described the clinical symptoms 
of factor complex, a complex which can be present as a combination of six cardinal signs: 
tremor, rigor, bradikinesia-hypokinesia, curve pose, lose of postural reflexes and freezing 
phenomena. To get to the final diagnose, the clinicians usually use the Brain Bank Criteria of 
UKPDS [9]. 
Generally, there are four categories of Parkinsonism: Idiopathic Parkinson Disease; 
Secondary Parkinsonism; Parkinson plus syndrome and   other neurodegenerative diseases 
in which Parkinsonism is main clinical manifestation [7]. 
Idiopathic Parkinson disease is the most represented type of Parkinsonism and it is 
maintained in almost 80 percents of the patients with movement disorders. Mostly with 
unilateral presentation, well respons on Dopamine-agonists and Levodopa, characterized 
with general slowness and typical tremor, from 4 to 6 Herz. 
The basic patho-anatomical findings in patients with Idiopathic Parkinson Disease, is loss of 
neurons which contain neuromelanin. These neurons are located in particular parts of the 
brain, such as substantia nigra and locus ceruleus. Dopamine level is reduced for almost 80 
percents under normal level, especially in striatum [7]. 
Hystopatological findings direct to presence of intracellular inclusions called Lewy-body, 
primary in substantia nigra, and they contain alpha-synuclein. 
Alpha-synuclein is present in many parts of the brain, but mostly in substantia nigra, and it 
is the only synuclein included in Parkinson disease. It was found that two non-sence 
mutations in gene of alpha-synuclein, A53T and A30P, are closely related with early 
appearance of Idiopathic Parkinson Disease between populations in Europe. Accumulation 
of this protein in dopaminergic neurons is responsible for the process of neurodegeneration 
[20]. 
2. Aims 
1. To determinate age, sex and difficulty of clinical manifestations in patients with 
Idiopathic Parkinson Disease, using UPDRS scale. 
2. To compare the findings of genetic researches, by age and sex in patients with 
Idiopathic Parkison's Disease, with those in control group. 
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3. Materials and methodes 
This is a prospective study, clinical and genetic, approved by the Ethical Committee, at 
Medical Faculty of Skopje. The clinical part of the study was made at University Clinic of 
Neurology in Skopje. Laboratory and genetic part of the study was made at the laboratory of 
molecular biology at Faculty of Math and Natural sciences at University of “St. Cyril and 
Methodius” in Skopje. 
In the study were included and were analyzed 30 patients. At each of them, Idiopathic 
Parkinson Disease was diagnosed, by using many diagnostic criteria such as: History of the 
patient’s disease; Neurological examination; Neurophysiologic examinations such as EEG, 
ENMG, EP (VEP, SEP, BAEP); Neuroimaging methods, such as CT scan and MRI of brain; 
Neuropsychological tests.  
4. Genetic analysis: Detection of mutations in gene of alpha-synuclein 
(SNCA) 
DNA Isolation: under aseptic conditions, from each one of the patients, blood sample was 
taken, with the function of a vein. Each of those blood samples are kept invaccum pots 
(Vaccutainer), and anticoagulant  EDTA Na2 is added in each of the pots. 
Amplification: amplification of regions of SNCA gene was made with polymerase chain 
reaction. 
Detection of mutations: to detect the mutations in selected regions of SNCA gene, polymerase 
chain reaction- Restriction Fragment Length Polymorphism, was used. 
Amplification of the region of egzon 3 of SNCA gene was made, using the primers 5’- GTC 
TCA CAC TTT GGA GGG TTT C-3’ and 5’ CAC CTA CCT ACA CAT ACC TCT GAC and 
TC-3’. 
PCR amplification of region of egzon 4 of SNCA gene was made by using the primers 5’ 
GCT AAT CAG CAA TTT AAG GCT AG-3’ and 5’ GAT ATG TTC TTA GAT GCT and 
CAG-3’. All of these amplifications have length of 215 bp. 
Amplificated products were digested with appropriate restrictive endonuclease under the 
optimal conditions.  
G88C mutation in egzon 3 of SNCA gene was detected with restricted digestion with 
enzyme Mval. 
G209A mutation in egzon 4 of SNCA gene was detected with enzyme Mael. 
5. Results 
In this part of the article, we have a presentation of the results gained with processing, in 
other words, a statistic data analysis, needed for fulfilling the research aims set. 
As respondents in the research, we’ve included 32 patients with clinically confirmed 
Idiopathic Parkinson’s disease (IPD), diagnosed to Brain Bank Criteria, treated in the 
University Clinic of Neurology in Skopje – ward for extra pyramidal diseases. 
The gender structure of the respondents is presented with 18 (56.25%) males and 14 (43.75%) 
females, table 1 and picture 1. 
The average age of the respondents is 52, 7+10.3 years. The youngest respondent is 30 years 
and the oldest is 78 years. The median value with value of 50 years shows that 16 of the 
respondents (50%) are in the age group of 50-59 years, and even 23 of the patients are older 
than 50 years, table 2 and picture 2. 
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Gender N % 
Males 18 56.25 
Females 14 43.75 
Total 32 100 
Table 1. Respondents distribution by gender 
 
Fig. 1. Respondents distribution by gender 
 
Years N % 
30-39 4 12.5 
40-49 5 15.62 
50-59 16 50.0 
60-69 5 15.62 
70 > 2 6.26 
Total 32 100 
Mean = 52.75±10.3 
Median = 50 
Min=30 Max=78 
Table 2. Respondents distribution by age 
In table 3 and picture 3, the representation of neurological symptoms with extra pyramidal 
origin, typical for diagnosed with IPD, is presented. 
The objective neurogical finding, confirmed the presence of rigidity and hypertonia with 
extrapyramidal origin, to all 32 respondents. This also happened with tremor, which is one 
of the key symptoms of IPD. 
Dyskinesia, as a symptom of long-lasting usage of substitution therapy (levodopa), is found 
in 15 patients (46.9%) and lack of these symptoms is seen in 17 patients (53.1%). 
 
Symptoms Rigidity Tremor Dyskinesia 
Number % Number % Number % 
Present 32 100 32 100 15 46.88 
Absent  / / / / 17 53.12 
Total 32 100 32 100 32 100 
Table 3. Rigidity, tremor and dyskinesia distribution 
56,25
43,75
mal
femal
www.intechopen.com
 
Neuroimaging for Clinicians – Combining Research and Practice 
 
222 
12,5
15,62
50
15,62
6,26
0
5
10
15
20
25
30
35
40
45
50
%
30-39
40-49
50-59
60-69
70>
 
Fig. 2. Respondents distribution by age 
 
 
Fig. 3. Rigidity, tremor and dyskinesia distribution 
Bradykinesia or stuntment in movements, as main of the list of cardinal symptoms, 
according to Brain Bank Criteria of UK Parkinson’s Disease, was found present in all 
respondents. 
Reduced postural reflexes are positive in dominant number of respondents, 31 (96.6%). 
Bradydilalia or the changes in speech (stunt and monotonous speech), is found in 28 
patients (87.5 %) and in 4 of our patients (12.5%) a fully normal speech is present, table 4 and 
picture 4. 
Dominant patients with bradydilalia are those with minimal changes in speech, estimated 
by UPDRS scale, with 1 are 16 patients(50%), with 2,8 patients (25%), with 3 and 4, 2 
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patients(6.25%) and in 4 patients(12.5%) a fully normal speech is present and the speech 
itself is estimated with 0, according to UPDRS scale. 
 
Symptoms 
Bradykinesia 
Reduced postural 
reflexes 
Bradylalia 
Number % Number % Number % 
Present 32 100 31 96.87 28 87.5 
Absent / / 1 3.13 4 12.5 
Total 32 100 32 100 32 100 
Table 4. Bradykinesia, reduced postural reflexes and bradydilalia distribution 
 
 
 
 
Fig. 4. Bradykinesia, reduced postural reflexes and bradydilalia distribution 
The respondents gained the following neurophysiologic examinations: visual evoked 
potentials (VEP), somatosensory evoked potentials (SSEP), acoustic evoked potentials 
(BAEP) and electroencephalography (EEG). 
The VEP is with proper finding in 29 respondents (90.6%), 2 of them (6.3%) have prolonged 
latency and the finding of one respondent shows low-volted response, table 5  and picture 5. 
 
VEP N % 
Proper finding 29 90.62 
Low-volted response 1 3.12 
Prolonged latency 2 6.26 
Total 32 100 
Table 5. Visual evoked potentials (VEP) in patients with IPD 
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30 of the respondents have proper finding of somatosensory potentials SSEP and in 2 of 
them (6.2%), those potentials show low-volted responses, table 6 and picture 6. 
 
 
Fig. 5. Visual evoked potentials (VEP) in patients with IPD 
 
SSEP N % 
Proper finding 30 93.75 
Low-volted responses 2 6.25 
Total 32 100 
Table 6. Somatosensor evoked potentials in patients with IPD 
 
 
Fig. 6. Somatosensory evoked potentials in patients with IPD 
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22 of the respondents (68.7%) have proper finding of caustic evoked potentials BAEP and 10 
of them (31.2%) are with low-volted responses, table 7 and picture 7. 
 
BAEP N % 
Proper finding 22 68.75 
Low-volted responses 10 31.25 
Total 32 100 
Table 7. Caustic evoked potentials BAEP in patients with IPD 
 
 
Fig. 7. Caustic evoked potentials BAEP in patients with IPD 
19 of the responders (59.4%) have proper finding of electroencephalography; the finding of 
12 of them (37.5%) shows unstable basic brain activity, without pathological graph elements 
and in only one patient, unstable brain activity with presence of different types of 
pathological graph elements is found, table 8 and picture 8. 
 
EEG findings N % 
Proper finding 19 59.37 
Unstable basic brain activity without pathological 
graph elements 
12 37.5 
Unstable basic brain activity, with presence of 
pathological graph elements  
1 3.13 
Total 32 100 
Table 8. EEG in patients with IPD 
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Fig. 8. EEG in patients with IPD 
 
CT and MRI of brain findings N % 
Proper finding 12 37.5 
Discrete cortical reductive changes 11 34.37 
Global cortical reductive changes 9 28.13 
Total 32 100 
Table 9. CT and MRI of brain in patients with IPD 
 
 
Fig. 9. CT and MRI of brain in patients with IPD 
All patients gained neuroimaging examinations (CT and MRI of brain) and the examination 
results are presented in table 9 and picture 9. 
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In 12 patients (37.5%), the results of CT and MRI of brain are normal; 11 (34.4%) have 
discrete cortical reductive changes and 9 (28, 1 %) have global cortical changes. 
Doppler color sonography of the extra cranial blood vessels is with proper finding in 20 
respondents (62.5%), 7 (21.9%) are with lightly expressed intimacy and proper 
hemodynamic parameters; 5(15.6%) have expressed arteriosclerosical changes of carotidal 
blood vessels, table 10 and picture 10. 
 
Doppler color sonography of the carotid system N % 
Normal finding 20 62.5 
Lightly expressed intimacy with proper chemo dynamic 
parameters 
7 21.87 
Expressed arteriosclerotic changes of the blood vessels of the 
carotid system 
5 15.63 
Total 32 100 
Table 10. Doppler color sonography of the carotid system in patients with IPD 
 
 
Fig. 10. Doppler color sonography of the carotid system in patients with IPD 
In tables 11a and 11b, the results of the neuropsychological testing are shown. It’s visible 
that only 3 patients (9.4%) have proper cognitive capacities. In table 11a all 
neuropsychological findings are examined individually, with percentage representation in 
our 32 respondents. Depression is found in 24 patients (84.4%); anxiety in 3 patients (9.4%); 
in 13 patients (40.6%), initial or global cognitive and mnestic reduced changes are found. 
In table 11b, a statistic analysis of different combinations of findings from 
neuropsychological testing is presented, so between the patients dominant are those with 
depression and initial reduced cognitive capacities, as well as global reduced cognitive 
capacities. According to the frequency of occurrence, next is the finding of depression and 
global reduced cognitive and mnestical capacities, found in 3 respondents (9.4%). 
The rest findings from the neuropsychological testing: depression, anxiety, initial reduced 
cognitive capacities, depression and anxiety together, as well as the mutual presence of 
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depression and anxiety, joined with initial reduced cognitive and mnestical capacities, are 
found only in one of the respondents. 
 
Neuropsychological testing N % 
Proper finding 3 9.37 
Depression  27 84.37 
Anxiety 3 9.37 
Initial reduced cognitive and mnestical capacities 13 40.62 
Global reduced cognitive and mnestical capacities   13 40.62 
Table 11.a. Neuropsychological testing of respondents with IPD 
 
Neuropsychological testing N % 
Proper finding 3 9.37 
Depression 1 3.12 
Anxiety 1 3.12 
Global reduced cognitive and mnestic capacities 10 31.25 
Initial reduced cognitive and mnestic capacities 1 3.12 
Depression and anxiety 1 3.12 
Depression and global reduced cognitive and mnestic capacities 3 9.37 
Depression and initial reduced cognitive and mnestical 
capacities 
11 34.37 
Depression and anxiety and initial reduced cognitive and 
mnestical capacities 
1 3.12 
Total 32 100 
Table 11.b. Neuropsychological testing of respondents with IPD 
 
UPDRS Gender 
Total 
Males Females 
Minimal signs 2 
11.11% 
9 
64.29% 
11 
Light signs 9 
50.00% 
4 
28.57% 
13 
Expressed symptoms 3 
16.67% 
1 
7.14% 
4 
Extremely expressed symptoms 4 
22.22% 
0 4 
Total 
% of total number 
18 
56.25% 
14 
43.75% 
32 
Table 12. The immensity of the clinical state, according to the respondents’ gender Mann-
Whitney U=47,5  Z=2,98  p=0,0029  
The immensity of the clinical state of Parkinson’s disease in our respondents, of different 
gender, is presented in table 12 and picture 11. The male respondents have significantly 
tougher clinical state comparing to female respondents. This statistic comment is a result of 
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the distribution shown in the table. It is noticeable that half of the male respondents (9.50%), 
have light disease symptoms; 2 (11.1%) have minimal signs or symptoms according to 
UPDRS scale; 4 (22.2%) are with extremely visible symptoms. In the female respondents, the 
disease is often manifested with minimal symptoms; 9(64.3%) and 4(28.6%) have light 
symptoms and there aren’t any female respondents with extremely visible symptoms. 
 
 
Fig. 11. The immensity of the clinical state, according to the respondents gender 
The average age of the respondents, which according to UPDRS scale, have minimal 
symptoms of Parkinson’s disease, is 53, 6+10.3 years. 
The respondents with light signs have average age of 52.8+8.1 years; the respondents with 
extremely expressed symptoms have average age of 45+15.3 years, table 13 and picture 12. 
 
UPDRS N Age (Mean) Age (SD) 
Minimal signs 11 53.63 10.28 
Light signs 13 52.85 8.10 
Expressed signs 4 57.75 11.73 
Extremely expressed symptom 4 45.00 15.30 
Table 13. The immensity of the clinical state (UPDRS), according to the patient’s age 
The connection between the age and the immensity of the clinical state of the respondents, 
estimated by UPDRS scale is presented in picture 13. That correlation has value for 
Spearmenov’s correlation coefficient, R=0.039, which indicates indirect or negative 
correlation. Parkinson’s disease has more difficult clinical state in younger patients and vice 
versa lighter symptoms in older patients. But, considering the value of the coefficient, we 
can conclude that the correlation between these two parameters is weak and statistically 
insignificant (p>0.05). 
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Fig. 12. The immensity of the clinical state (UPDRS), according to the patient’s age 
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Fig. 13. Correlation between the immensity of the clinical state, according to UPDRS and the 
age of the respondents with IPD 
53,63 52,85
57,75
45
0 
10 
20 
30 
40 
50 
60 
Minimal 
signs 
Light
signs
Expressed
signs 
Extremely expressed
signs 
Mean (adge)
www.intechopen.com
 
Clinical and Genetic Aspects in Patients with Idiopathic Parkinson Disease 
 
231 
6. Spearman rank order correlations R=-0.039 p>0.05 
In our research, we’ve concluded that direct or positive statistic significant correlation 
between the number of hospitalizations and the immensity of the clinical state, according to 
UPDRS, indeed exists. 
The value of the Spermen’s coefficient (r=0.48), shows that these two parameters are 
proportionally connected, in other words, patients with IPD difficult manifestations of the 
disease, according to UPDRS scale, have more hospitalizations in the University clinic of 
Neurology in Skopje. 
Table 14 and picture 14, show the results from the crostabulation between the CT finding 
and MRI of brain and the immensity of the clinical state, determined according UPDRS 
scale. In the respondents group with light disease symptoms, according to UPDRS scale, 
dominant are the findings with normal level, previously determined with CT and MRI of 
brain, present in 5 patients (45.4%), from this group. Between the respondents with light 
disease symptoms, the finding from CT and MRI of the brain shows discrete cortical 
reduced changes in 6 patients (46.1%). In half of the respondents, the finding from CT and 
MRI of brain, shows presence of discrete cortical reduced changes.75% of the respondents 
with highly expressed disease symptoms, have global cortical reduced changes, proved on 
CT and MRI of brain. 
 
CT and MRI of 
brain 
Immensity of the clinical state (UPDRS) 
Total Minimal 
signs 
Light signs 
Expressed 
signs 
Extremely 
expressed 
signs 
Normal finding 5 
45.45% 
5 
38.46% 
1 
25.00% 
1 
25.00% 
12 
Discrete 
cortical 
reductive 
changes 
3 
27.27% 
6 
46.15% 
2 
50.00% 
0 11 
Global cortical 
reductive 
changes 
3 
27.27% 
2 
15.38% 
1 
25.00% 
3 
75.00% 
9 
Total 11 13 4 4 32 
Table 14. Immensity of the clinical state (UPDRS) in relation to CT and MRI of brain 
The connection or the correlation between the immensity of the clinical state, determined by 
UPDRS scale and brain CT/MRI finding, is also proved with the usage of Spearsmen’s 
correlation coefficient. Its value (r=0.2) shows presence of direct, positive correlation 
between these two parameters, in other words, there is a match between the brain CT/MRI 
finding and the results from the UPDRS scale. In patients with difficult clinical forms of IPD, 
most often the brain CT/MRI finding shows global cortical reduced changes. But, the 
confirmed correlation is statistically insignificant, (p>0.05), picture 15. 
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Fig. 15. Correlation between the immensity of the clinical state (UPDRS) and brain CT/MRI 
finding Spearman Rank Order Correlations R=0, 2 p>0.05 
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7. Mutation detection 
After amplification of a region from egzon 3 of SNCA gene, with usage of the following 
primers: 5’GTC TCA CAC TTT GGA GGG TTT C-3 and 5’-CAC CTA CCT ACA CAT ACC 
TCT GAC TC-3’, the result was an amplified product with length of 395 base pairs (bp). PCR 
amplification of a region from egzon 4 of SNCA gene, was performed with these primers 5’-
GTC AAT CAG CAA TTT AAG GCT AG-3’ and 5’-GAT ATG TTC TTA GAT GCT CAG-3’, 
and the amplifications have length of 215 bp. The amplified products were digested with 
proper restrictive endonuclease under optimal conditions (puferian solutions suitable for 
each enzyme separately on temperature of 37 c). With that, no mutated sequence in the PCR 
product is found. 
G88C mutation in egzon 3 of SNCA gene isn’t detected in our 32 respondents with IPD. No 
mutations were found in the G209A in the enzon 4 from SNCA gene, also. 
 
 
Fig. 16. Electroforetogram from PCR-RELP analysis (agaros gels colored with etidium 
bromide and photographed on ultraviolet light. 
 
 
Fig. 17. Electroforetogram from PCR-RELP analysis (agaros gels colored with etidium 
bromide and photographed on ultraviolet light 
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8. Discussion 
IPB is found in both genders, with discretely higher representation in males. Our study 
shows that the gender representation for 32 patients with clinically confirmed diagnosis of 
JPB, by Brain Bank Criteria, is 18 males (56.25%) and females (43.75%). In most studies, as 
those of Haksma and all. (2007), Lions and all (2009); Linder and all. (2010), conducted in 
different periods and different populations, the results have big similarity with ours (8, 17, 
and 12). 
In our study the average age of the respondents is 52.7 years. The youngest is only 30 years 
and the oldest is 78 years. The median value (50 years) shows that 16 respondents (50%) are 
in the age group of 50-59 years, and even 23 patients (71.87%) are older than 50 years (table 
2, picture 2 from the results). 
From the analyzed articles about the average beginning of IPD, dominant are those where 
the average beginning is in the sixth decade from life [21, 16, and 1]. 
Alves and all. (2009) in their epidemiological study in Norway, conducted on 554 patients 
with IPD, noted that the average age for beginning of symptoms manifestation of IPD is 54.3 
years (this fits perfectly with the average age of our 32 respondents) [1]. 
Bradykinesia or the of stuntment in movements, as main from the list of cardinal symptoms 
according to Brain Bank Criteria of UK Parkinson’s Disease (BBC-UKPCD), was present in 
all respondents. According to BBC-UKPCD criteria, to set the JPD diagnosis, the patient 
should have bradykinesia plus one of the rest cardinal symptoms such as tremor, rigidity or 
reduced postural reflexes. With the presence of only 2 symptoms (from which one must be 
bradykinesia) IPD can be confirmed. 
Bradykinesia as cardinal symptom according to UPRDS, was estimated in the following 
way: 15 patients (47.87%) with 1; 10 (31.25%) with 2; 5 (15.62%) with 3 and only 2 
respondents (6.25%) with 4 according to UPRDS scale. 
Stefanie Lui and all. (2009) in their study make analysis of the development of bradykinesia 
as symptom in different disease stadiums. According to them, the disease progression is 
influenced from the bradykinesia as main cardinal symptom [19]. 
When our respondents are in question, in only one of them (3.12%), the lack of symptom 
reduced postural reflexes was confirmed and its value was 0, according to UPDRS scale. In 
our respondents, 75% had reduced postural reflexes, estimated with 1; 5 (15.62 %) with 2 
and 1 (3.12%) were with values of 3 and 4. 
Spildoren I and all. (2010), in their article described the postural instability as common and 
very important symptoms in IPD. In their patients, this instability is seen through partial 
walking instability in the initial disease stadium and as freezing phenomena in the 
advanced disease stadiums. According to them, the freezing phenomena are often expressed 
in simultaneous double activities and in the act of turning after short walking [13]. 
Kerstin Ziegler and all. (2010), describe festination and freezing in all 33 patients with more 
advanced stadium of IPD. The way they estimated festination and freezing in walking, was 
with 12 episodes walking capturing, in which motor block was seemed in 4 situations with 3 
levels of double activities. Practically, these phenomenas are reflected in parameters 
expressed by measuring the number of steps of those patients, walking on special stripe and 
analysis on walking on distance of 10 meters. This is how you make assessment on 
expression of the postural instability [14]. 
Besides bradykinesia, as main cardinal symptom, as symptoms od IPD, are also found 
tremor and rigidity. We’ve found their presence in all our respondents (100%). 
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Tremor is estimated with 2, according to UPDRS scale in 18 respondents (56.25%); 10 
(31.25%) with 1; 3 (9.4%) with 3 and only one patient (3.1%) we’ve found tremor estimated 
with 4. 
Petra Vingensuh and all (2010) conducted examination on 25 respondents in initial stadium 
of IPD. In all of them, unilateral tremor pointed with bradykinesia was found, and it was 
possible to make diagnosis. Additionally, all these patients gained SPECT testing and in 
only 10% a proper finding of SPEKT was found. Lately, a number of articles are published, 
which through examination of cardinal secondary symptoms in patients with IPD, make 
analysis on their life quality. In our article, the estimation of the immensity of the clinical 
state was made using the UPDRS scale, which is generally accepted and applied in most 
scientific articles for Parkinson’s disease [6]. 
The correlation between respondents’ age and the immensity of the clinical state, estimated 
according to UPDRS scale, is shown in picture 26 in our results. This relation points the 
existence or negative correlation. Parkinson’s disease has fairly difficult clinical state in 
younger patients and vice verse; the disease is manifested with lighter symptoms in elder 
patients. But, considering the coefficient value, we can conclude the correlation between 
these two parameters is statistically insignificant (p>0.05). 
Barone P and all. (2009), this multicentrical article shows the frequency of the nonmotor 
signs and symptoms such as hyposmia, mood, sleeping, tiredness, perception difficulties, 
attention, memory capacity, erectil disfunction [3]. 
All these signs are examined in patients on different disease stadiums, and than analyzed to 
present their influence on the life of these patients. 
The authors monitor 524 patients with Parkinson’s disease, and they register their nonmotor 
symptoms and their influence on patients’ life in different disease stadiums. They stated, 
that in younger patients the clinical state is tougher according to UPDRS, comparing to elder 
patients. Also, the study witnessed that disease progression is much faster in younger 
patients comparing to elder patients [3]. 
Keush SH and all. (2009), conducted their clinical examination of motor and nonmotor 
symptoms of Parkinson’s disease in Holland. The authors developed a specific scale through 
which, the possibilities and capabilities for daily activities were analyzed, and according to 
which the degree of disease progression can be determined. 
According to them, in younger patients we have faster symptoms progression, comparing to 
patients where the clinical state is manifested later [15]. 
The immensity of the clinical state of Parkinson’s disease in our respondents of different 
gender, show that male patients have significantly tougher clinical state comparing to 
female patients. 
Ivi Miler and Golomb AC (2010) made interesting, clinical-epidemiological study, in which 
is clearly shown that the disease is nearly equally manifested in two genders, but specific 
symptoms are more frequent in females and others in males. Motor symptoms which appear 
as a consequence of reduced function of dopaminerigic system, those which we often 
examine, are dominant in males, and only rigidity as motor symtoms and nonmotor signs 
are dominant in females [11]. 
It is assumed that this difference in manifestation by gender, most likely, is influenced by 
unknown hormonal mechanisms. 
From the list of the neuropsychological examinations, the respondents gained: visual 
evoked potentials (VEP); somatosesoral evoked potentials (SSEP); caustic evoked potentials 
(BAEP) and electroencephalography (EEG). Generally in our 32 respondents, the most 
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findings for evoked potentials (VEP, SSEP and BAEP) are proper. Proper VEP is found in 29 
respondents (90.6%); prolonged latencies and low-volted responses are found in 2 (6.3%) 
and only in 1 respondent (3.1%), the finding is with low-volted response. 
SSEP is with proper finding in 30 respondents (93.8%) and low-volted responses are found 
in 2 (6.2%). Proper BAEP finding is found in 22 (68.72%) and low-volted different 
components are found in 10 (31.25%). 
In our patients, neuroimaging examination (CT and MRI of brain) are made; 37.5% have 
proper results; in 34.4% of them discrete cortical reduced changes are found and in 28.1% 
the pathological process is manifested with global cortical reduced changes. 
Doppler color sonography on extra cranial blood vessels, shows proper finding in 62.5% of 
the respondents; in 21.9% lightly expressed intimacy and proper chemo dynamic 
parameters are found; in 15.6% of our patients have arteriosclerotical changes of the caroted 
blood vessels. 
Lio CH and all. (2010) made a study on 84 patients with IPD, without dementia signs. They 
made several short capturing with MRI of brain, examining the regions which are most 
often damaged in these patients. Patients with medium developed clinical state were 
selected. They also had plenty symptoms and the exact regions which influenced the 
domination on specific motor and nonmotor symptoms, were determinated.  Dementia as a 
symptom was excluded [4]. 
Table 11a and 11b from our results, presents the results from the neuropsychological testing. 
Proper cognitive capacities of testing were found only in 3 patients with IPD. Between the 
patients dominant are those with depression and initial reduced cognitive capacities 
(34.4%), as well as 31.2% with global reduced cognitive capacities. 
According to the frequency of occurrence, next is the finding of depression and global 
reduced cognitive capacities, found in 9.4% of our respondents. 
The rest findings of the neuropsychological testing: depression in behavior, anxiety in 
behavior, initial reduced cognitive capacities; depression and anxiety in behavior, as well as 
the mutual presence of depression and anxiety in behavior and initial reduced cognitive 
capacities are found only in 1 patient with IPD. 
Lately, in different magazines and congresses, scientists try to prove the correlation between 
the IPD and depression as secondary symptom, as well as, dementia, found in high percent 
of patients with Parkinson’s disease. 
Ivi N Miler and Golumb AC (2010) made interesting clinical and epidemiological study, 
where they proved that the disease is nearly equally manifested in both genders. But, certain 
symptoms more often appear in females and other in males. Etiopathogenetical mechanisms 
for these symptoms division, is still unknown, but it is assumed that the hormonal status 
influences on manifestation of these symptoms. Consequently, the nonvoter symptoms 
(mood, hyposmia, sleeping, attention, memory, perception difficulties and depression) are 
dominant in females [11]. 
Huijuan Li and all. (2010), made a study on 82 Chinese patients, 46 males and 36 females 
with IPD, which lasted 18 months. Patients were on average age of 65 years. Generally, they 
examined the motor signs such as: mood, sleeping, depression, attention, memory capacity 
and perception disorder. To determinate the degree of disease, the authors used UPDRS 
scale. Then using a special scale for determination of nonmotoral symptoms development, 
they determined the degree of these symptoms. They concluded that there is a positive 
correlation between the development of the nonmotor and psychological symptoms in 
relation to the development of motor signs of the disease, according to UPDRS. Actually, all 
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these symptoms, nonmotor and motor, develop parallel, meaning that in the early disease 
stadiums, all symptoms are lightly developed, no matter what they are like, while in the 
more advanced stadiums, all symptoms are expressed and visible [10]. 
Ajlin Juxel and all. (2010) in their study of 28 patients with IPD, conducted in Turkey, made 
multiple capturing with nuclear magnetic resonance on brain (MRI), measuring the 
thickness of brain callus in different brain regions. A correlation between the immensity of 
the clinical state, determined by UPDRS scale and the finding from MRI (measurement of 
the brain callus thickness), was set. The authors concluded that the thinner brain callus is, 
the more developed the clinical state of patients with IPD is [2]. 
In our study, G88C mutation in egzon 3 form SNCA genes isn’t detected in our 32 
respondents with IPD. The same happens with G209A in egzon 4 form SNCA gene. 
Suterland GT and all (2009) in their immense study conducted on Australian population, of 
331 patients with scattered form and family form of Parkinson’s disease and 296 healthy 
people. The authors examined 11 known genes and all kinds of combinations of these genes 
correlations with symptoms manifestations of Parkinson’s disease. They concluded that only 
LRRK2 gene has hardly any influence only in the family form of Parkinson’s disease, while 
the rest genes, between which SNCA, have no influence at all in scattered Parkinson’s 
disease manifestation in Australians, a result which fits the findings of our research [20]. 
Sarah Kamargos and all. (2009) made a study to evaluate the frequency and the 
phonotypical and genotypical manifestation in family and scattered forms of Parkinson’s 
disease in Brazilian population. The examination was conducted on 575 patients with 
Parkinsonism, where the ones with IPD are 428. Mutations and polymorphisms on many 
different genes, typical for Parkinson’s disease, such as alpha synuclein and LRRK2 gene, 
were examined. In the end, they concluded that there wasn’t any mutation on alpha 
synuclein in all respondents and in only one patient with initial symptoms of IPD, a slight 
mutation of LRRK2 gene, was found [18]. 
Kristian Vajder and all. (2009), made immense study on 1262 patients with IPD and control 
group of 1881 patient. They checked the correlations between the fibroblastic growing factor 
20 and alpha synuclein in patients with Parkinson’s disease. They examined their 
correlations on 9 brains on deceased patients, which were previously diagnosed with IPD. 
The authors concluded that the role of alpha synuclein in Parkinson’s disease is 
undisputable, but the changes in sequences in this gene, were negative [5]. 
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